Finanzas de AC Immune AG (ACIU)ACIUAC Immune AG

Evaluating the bottom line, AC Immune AG maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 7.89%, while the net margin is 12.40%. These profitability ratios, combined with a Return on Equity (ROE) of -78.53%, provide a clear picture of how effectively ACIU converts its operational activities into shareholder value.

In the context of the broader market, ACIU competes directly with industry leaders such as BCYC and AMRN. With a market capitalization of $240.61M, it holds a significant position in the sector. When comparing efficiency, ACIU's gross margin of 100.00% stands against BCYC's 100.00% and AMRN's 35.51%. Such benchmarking helps identify whether AC Immune AG is trading at a premium or discount relative to its financial performance.

The company has shown significant revenue growth, with Q2 revenue reaching 19.1 million CHF, and a notable net income recovery in the same period, indicating improved profitability.